Launching a Study of Rapamycin in Older Patients with Gum Disease
Recent data on mTOR inhibition by rapamycin suggests it as a promising approach to slow aging, with greater life span extension in animal models than exercise. Human studies on rapamycin and aging are lacking, making it exciting to see a new study funded to test this drug in older individuals with gum disease. The study aims to collect valuable biomarker data on health and aging, expanding our understanding of the potential benefits of rapamycin beyond anecdotal evidence.
The clinical trial will investigate the effects of rapamycin on patients with gum disease, focusing on its anti-inflammatory properties and potential impact on healthy aging. The study will also analyze changes in participants’ microbiomes and biological clocks, aiming to uncover new insights on age-related diseases. This trial could pave the way for future research on rapamycin’s role in slowing down various age-related conditions.
